A Phase 3 interventional study of Metronidazole and Ceftriaxone sodium in Intra-abdominal Infections, sponsored by Pfizer. Completed at 15 sites in Japan. Open to participants aged 16 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-01-24.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Intraabdominal Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Intraabdominal Infections · Pfizer.
Among the 19 studies in Intraabdominal Infections by Pfizer, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 9th registered.
129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.
Browse Intraabdominal Infections studies →None of the 19 studies in Intraabdominal Infections by Pfizer is open now. The open studies under Intraabdominal Infections, anywhere →
Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 16 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.
Median enrollment 144 across the 14 interventional studies, 203 across the 5 observational. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Intraabdominal Infections by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the clinical efficacy and safety in Japanese adult subjects with Intra-abdominal/Pelvic infections receiving Metronidazole IV 1,500-2,000 mg/day in combination with ceftriaxone sodium.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium
Drug: Metronidazole · Drug: Ceftriaxone sodium
Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
Also known as: ROCEPHIN
Clinical Response: Response Rate (Data Review Committee Assessment)
Clinical response was evaluated by the data review committee as effective (cured or improved), ineffective (not meeting "effective" criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; "number of participants evaluated as effective" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.
Time frame: Baseline to EOT (up to 14 days), TOC
Clinical Response: Response Rate (Investigator Assessment)
Clinical response was evaluated by the investigator as effective (cured or improved), ineffective (not meeting "effective" criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; "number of participants evaluated as effective" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.
Time frame: Baseline to EOT (up to 14 days), TOC
Percentage of Participants Who Was Assessed as Appropriate to Continue Treatment (Investigator Assessment)
The appropriateness of treatment continuation was evaluated on Day 4 by the investigator as continuation, discontinuation or indeterminate based on the clinical response. The percentage of participants was calculated from the following formula; "number of participants assessed as continuation" over "total number of participants that excluding ones assessed as indeterminate" multiplied by 100.
Time frame: Baseline to Day 4
Bacteriological Response: Eradication Rate (Data Review Committee Assessment)
Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the data review committee, at Day 4, at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, "number of participants with bacteria eradication, presumed eradication or colonization" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.
Time frame: Baseline to Day 4, EOT (up to 14 days), TOC
Bacteriological Response: Eradication Rate (Investigator Assessment)
Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the investigator at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, "number of participants with bacteria eradication, presumed eradication or colonization" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.
Time frame: Baseline to Day 4, EOT (up to 14 days), TOC
Number of Participants Analyzed for Population Pharmacokinetics (PK) of Metronidazole
Population pharmacokinetic analysis of Metronidazole is conducted by combining current study data with other Metronidazole studies.
Time frame: Four samples were taken at any infusion after the first dosing: during infusion, immediately after end of infusion, between 15 and 60 minutes after end of infusion, and between 2 hours and immediately before the start of the next infusion.
| Milestone | Metronidazole/Ceftriaxone |
|---|---|
| Started | 38 |
| Completed | 32 |
| Not completed | 6 |
| Withdrew: Adverse event | 4 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Does not meet entrance criteria | 1 |
Clinical response was evaluated by the data review committee as effective (cured or improved), ineffective (not meeting "effective" criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; "number of participants evaluated as effective" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.
| percentage of participants | Metronidazole/Ceftriaxone |
|---|---|
| End of Treatment (n=30) | 96.6 (82.2 to 99.9) |
| Test of Cure (n=30) | 96.7 (82.8 to 99.9) |
Clinical response was evaluated by the investigator as effective (cured or improved), ineffective (not meeting "effective" criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; "number of participants evaluated as effective" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.
| percentage of participants | Metronidazole/Ceftriaxone |
|---|---|
| End of Treatment (n=30) | 96.7 (82.8 to 99.9) |
| Test of Cure (n=29) | 100.0 (88.1 to 100.0) |
The appropriateness of treatment continuation was evaluated on Day 4 by the investigator as continuation, discontinuation or indeterminate based on the clinical response. The percentage of participants was calculated from the following formula; "number of participants assessed as continuation" over "total number of participants that excluding ones assessed as indeterminate" multiplied by 100.
| percentage of participants | Metronidazole/Ceftriaxone |
|---|---|
| Percentage of Participants Who Was Assessed as Appropriate to Continue Treatment (Investigator Assessment) | 100.0 |
Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the data review committee, at Day 4, at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, "number of participants with bacteria eradication, presumed eradication or colonization" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.
| percentage of participants | Metronidazole/Ceftriaxone |
|---|---|
| Day 4 | 100.0 (75.3 to 100.0) |
| End of Treatment | 100.0 (83.2 to 100.0) |
| Test of Cure | 100.0 (83.9 to 100.0) |
Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the investigator at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, "number of participants with bacteria eradication, presumed eradication or colonization" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.
| percentage of participants | Metronidazole/Ceftriaxone |
|---|---|
| Day 4 | 100.0 (75.3 to 100.0) |
| EOT | 100.0 (83.2 to 100.0) |
| TOC | 100.0 (83.9 to 100.0) |
Population pharmacokinetic analysis of Metronidazole is conducted by combining current study data with other Metronidazole studies.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metronidazole/Ceftriaxone | — | 4/38 (10.5%) | 30/38 (78.9%) |
| Event | Metronidazole/Ceftriaxone |
|---|---|
| Infectious peritonitisInfections and infestations | 1/38 |
| Pelvic inflammatory diseaseInfections and infestations | 1/38 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/38 |
| Retroperitoneal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/38 |
| Event | Metronidazole/Ceftriaxone |
|---|---|
| DiarrhoeaGastrointestinal disorders | 12/38 |
| Ileus paralyticGastrointestinal disorders | 5/38 |
| InsomniaPsychiatric disorders | 5/38 |
| NauseaGastrointestinal disorders | 4/38 |
| VomitingGastrointestinal disorders | 4/38 |
| Abdominal distensionGastrointestinal disorders | 3/38 |
| Abdominal pain upperGastrointestinal disorders | 3/38 |
| Injection site painGeneral disorders | 3/38 |
| TinnitusEar and labyrinth disorders | 2/38 |
| ConstipationGastrointestinal disorders | 2/38 |
| Age, Continuous(years) | Metronidazole/Ceftriaxone |
|---|---|
| Mean | 48.9 ± 16.9 |
| Sex: Female, Male(Participants) | Metronidazole/Ceftriaxone |
|---|---|
| Female | 24 |
| Male | 14 |
The record gives a start of Nov 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metronidazole · Ceftriaxone